Company news
Nexalis Therapeutics Limited (ASX:NX1) news
Nexalis Therapeutics Limited news releases on 6ix. Latest, Sep 1, 2026: Removal of draft wording in the directors report HY accounts
Press releases & updates
Removal of draft wording in the directors report HY accounts
September 1, 2026
Jun26 Appendix 4C Cash Flow Report
July 30, 2026
Update on Funding Facility and Clinical Program
July 5, 2026
Binding Letter of Intent to replace existing $53m facility
May 27, 2026
Suspension from Quotation
May 25, 2026
Mar26 Appendix 4C Cash Flow Report
April 30, 2026
Significant Milestone - First Patient Screened IRX-211 Ph2
April 20, 2026
First patient dosed in IRX-616a Phase 1 trial
March 18, 2026
First eligible participant screened - phase 1 IRX-616a study
March 4, 2026
Preliminary Final Report
February 27, 2026
Dec25 Quarterly Activities Report
January 29, 2026
Dec25 Appendix 4C Cash Flow Report
January 29, 2026
IRX Overview Presentation - SRX-25 and Nexalis
December 9, 2025
$12.6m Facility to Drive SRX-25 Development
December 3, 2025
Prospectus - Non-Renounceable Rights Issue Offer
November 26, 2025
Drug Development Pipeline Bolstered and Capital Raise
November 26, 2025
Trading Halt
November 23, 2025
Sep25 Quarterly Activities Report
October 31, 2025
Sep25 Appendix 4C Cash Flow Report
October 31, 2025
Half Yearly Report and Accounts
August 25, 2025
Jun25 Quarterly Activities Report
July 22, 2025
Jun25 Appendix 4C Cash Flow Report
July 22, 2025
Mar25 Quarterly Activities Report
April 28, 2025
Mar25 Appendix 4C Cash Flow Report
April 28, 2025
IRX Completes First Drawdown Under Clendon Facility
April 24, 2025
IRX-616a Study Order Executed to Commence Phase 1
April 17, 2025
Study Order Executed for Phase 2 BTcP Trial
March 13, 2025
Updated Dec24 Quarterly Activities Report
January 24, 2025
Dec24 Quarterly Activities Report
January 23, 2025
Dec24 Appendix 4C Cash Flow Report
January 23, 2025
Shareholder Update
December 19, 2024
Issue of Securities Following General Meeting Approval
December 15, 2024
Ethics Approval for Phase 2 Clinical Trial of IRX-211
November 14, 2024
Sep24 Appendix 4C Cash Flow Report
October 31, 2024
Sep24 Quarterly Activities Report
October 31, 2024
$38.5m Funding to Fully Fund Clinical Development Plans
October 17, 2024
Issue of Shares to CEO in Lieu of Accrued Salary
October 2, 2024
Jun24 Quarterly Activities Report
July 31, 2024
Jun24 Appendix 4C Cash Flow Report
July 31, 2024
Mar24 Appendix 4C Cash Flow Report
April 30, 2024
Mar24 Quarterly Activities Report
April 30, 2024
Dec23 Quarterly Activities Report
January 16, 2024
Dec23 Appendix 4C Cash Flow Report
January 16, 2024
IRX211 - Targeted Pain Indication Nomination - BTcP
January 10, 2024
Significant Milestone - Completion of IRX211 Phase 1 Trial
December 3, 2023
Sep23 Quarterly Activities Report
October 31, 2023
Sep23 Appendix 4C
October 31, 2023
Quarterly Activities Report
July 30, 2023
Quarterly Appendix 4C Cash Flow Report
July 30, 2023
First Cohort Complete for Phase 1, Pain Indication IRX211
June 14, 2023